iTeos Therapeutics, Inc. (ITOS)
10.15
+0.02 (0.20%)
Inactive · Last trade price on Aug 28, 2025

iTeos Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
4492813926951,6421,185
Market Cap Growth
--28.39%-43.60%-57.70%38.57%-
Enterprise Value
-62-203-201-53745845
Last Close Price
10.157.6810.9519.5346.5633.82
PE Ratio
---7.197.66-
Forward PE
----10.82-
PS Ratio
-8.0231.112.604.76-
PB Ratio
0.790.480.681.052.973.67
P/TBV Ratio
0.910.480.681.052.973.67
P/FCF Ratio
----3.21-
P/OCF Ratio
----3.20-
EV/Sales Ratio
----2.16-
EV/EBITDA Ratio
----3.04-
EV/EBIT Ratio
----3.04-
EV/FCF Ratio
----1.46-
Debt / Equity Ratio
0.010.010.010.010.01-
Debt / EBITDA Ratio
---0.040.02-
Debt / FCF Ratio
----0.01-
Asset Turnover
-0.050.020.330.56-
Quick Ratio
7.3712.3513.4614.662.8322.45
Current Ratio
7.5312.6313.7614.962.8822.64
Return on Equity (ROE)
-34.97%-23.06%-18.19%15.90%48.98%-22.45%
Return on Assets (ROA)
-18.49%-14.47%-12.97%9.72%24.90%-14.97%
Return on Invested Capital (ROIC)
-21.76%-16.66%-14.77%13.00%34.73%-16.58%
Return on Capital Employed (ROCE)
---17.90%42.20%-
Earnings Yield
-45.11%-47.91%-28.75%13.91%13.06%-3.21%
FCF Yield
-24.23%-35.57%-27.24%-16.14%31.17%-2.15%
Buyback Yield / Dilution
-17.71%-13.17%5.30%0.02%-150.49%-7336.28%
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q